Stevanato Group S.p.A. (STVN), an Italian provider of industrial drug containment, drug delivery, and diagnostic solutions, on Wednesday initiated guidance for the full year.
For fiscal 2026, the company expects adjusted profit of €0.59 to €0.63 per share, with adjusted EBITDA of €331.8 million to €346.9 million, on revenue of €1.26 billion to €1.29 billion.
For fiscal 2025, the Group has reported adjusted profit of €0.54 per share, with adjusted EBITDA of €298 million, on revenue of €1.186 billion.
STVN was up by 5.09% at $15.48 in the pre-market trade on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.